ClinicalTrials.gg
RecruitingNCT07498907LUXUS41Updated Sep 28, 2026

Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma

A Phase 3 interventional study of Disitamab Vedotin (RC48) and radiotherapy in Upper Tract Urothelial Carcinoma, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Peking University First Hospital · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Sep 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized, open-label, multicenter phase III study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial carcinoma after radical nephroureterectomy (RNU). Eligible patients must have postoperative pathologic stage pT3-pT4N0M0 or pTanyN+M0, HER2 expression defined as immunohistochemistry (IHC) 1+, 2+, or 3+, and be cisplatin-ineligible. Patients will be randomized in a 2:1 ratio to receive disitamab vedotin plus radiotherapy or gemcitabine plus carboplatin. The primary endpoint is 3-year disease-free survival. Secondary endpoints include overall survival, metastasis-free survival, local recurrence-free survival, bladder recurrence-free survival, incidence of adverse events, and patient-reported quality of life.

02

Conditions studied

  • Upper Tract Urothelial Carcinoma

Keywords

  • UTUC
  • HER2
  • Disitamab Vedotin
  • Radiotherapy
  • Adjuvant Therapy
  • Cisplatin-Ineligible
  • Upper Tract Urothelial Carcinoma
03

In context

Lead sponsor

Peking University First Hospital is the lead sponsor of 392 studies on the registry; 187 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older.
  • confirmed upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU).
  • Postoperative pathologic stage pT3-pT4N0M0 or pTanyN+M0.
  • expression confirmed by immunohistochemistry (IHC 1+, 2+, or 3+).
  • Cisplatin-ineligible, defined as meeting at least one of the following criteria: performance status 2; \<60 mL/min; grade 2 or higher hearing loss; CTCAE grade 2 or higher peripheral neuropathy; or (NYHA) class III heart failure.
  • Adequate organ function.
  • Expected survival of at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • History of other active , except for adequately treated malignancies with low risk of recurrence.
  • Prior systemic antitumor therapy before study treatment, or unresolved toxicities from prior therapy.
  • Known to disitamab vedotin, related agents, or any component of the study treatment.
  • Severe active infection.
  • Not adequately recovered from surgery.
  • Pregnant or breastfeeding women.
  • Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    Disitamab Vedotin Plus Radiotherapy

    Participants in this arm will receive disitamab vedotin plus radiotherapy as adjuvant treatment after radical surgery for HER2-expressing,cisplatin-ineligible upper tract urothelial carcinoma.

    Drug: Disitamab Vedotin (RC48) · Radiation: radiotherapy

  • Active comparator
    Gemcitabine Plus Carboplatin

    Participants in this arm will receive gemcitabine plus carboplatin as adjuvant treatment after radical surgery for HER2-expressing cisplatin-ineligible upper tract urothelial carcinoma.

    Drug: Gemcitabine (1000 mg/m2) · Drug: carboplatin

Interventions

  • Disitamab vedotin 2.0 mg/kg (maximum 120 mg) will be administered intravenously every 2 weeks for 12 cycles as adjuvant treatment after radical surgery.

  • Radiationradiotherapy

    Adjuvant radiotherapy will be delivered to the regional lymphatic drainage area at 45-50 Gy in 25 fractions over 5 weeks. Suspicious lymph nodes will receive 62.5 Gy in 25 fractions over 5 weeks.

  • DrugGemcitabine (1000 mg/m2)

    Drug page: Gemcitabine

    Gemcitabine 1000 mg/m² will be administered on Days 1 and 8 of each 21-day cycle for 4 to 6 cycles as adjuvant treatment after radical surgery.

  • Carboplatin will be administered intravenously on Day 1 of each 21-day cycle at a target AUC of 4.5 to 5 for 4 to 6 cycles as adjuvant treatment after radical surgery.

06

What researchers measure

Primary outcomes

  1. 3-Year Disease-Free Survival

    Disease-free survival (DFS) is defined as the time from randomization to first recurrence in the tumor bed, first metastasis, or death from any cause, whichever occurs first.

    Time frame: From randomization up to 3 years

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) is defined as the time from randomization to death from any cause.

    Time frame: From randomization up to 3 years

  2. Metastasis-Free Survival

    Metastasis-free survival (MFS) is defined as the time from randomization to first documented distant metastasis or death from any cause, whichever occurs first.

    Time frame: From randomization up to 3 years

  3. Local Recurrence-Free Survival

    Local recurrence-free survival (LRFS) is defined as the time from randomization to first documented locoregional recurrence in the tumor bed or regional lymph nodes, or death from any cause, whichever occurs first.

    Time frame: From randomization up to 3 years

  4. Bladder Recurrence-Free Survival

    Bladder recurrence-free survival (BRFS) is defined as the time from randomization to first documented bladder urothelial recurrence or death from any cause, whichever occurs first

    Time frame: From randomization up to 3 years

  5. Incidence of Adverse Events

    Safety will be evaluated based on the incidence, type, severity, and attribution of adverse events during study treatment and follow-up.

    Time frame: From first dose through 30 days after completion of study treatment and up to 3 years for follow-up

  6. Patient-Reported Quality of Life

    Patient-reported quality of life will be assessed using validated quality-of-life questionnaires during treatment and follow-up.

    Time frame: Baseline through 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
May 1, 2026
Primary completionEst.
May 1, 2029
CompletionEst.
Mar 1, 2034
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 28, 2026
Sites
Peking University First Hospital is now Recruiting
Sep 28, 2026
Design
Phase 2→Phase 3
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Not yet recruiting→Recruiting
    Peking University First Hospital is now Recruiting
    Design Phase 2→Phase 3
    + 3 other changes: identifiers, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07498907
Collaborators
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
May 1, 2026
Primary completion
May 1, 2029 (estimated)
Completion
Mar 1, 2034 (estimated)
Last update
Sep 28, 2026

Study contacts

Xuesong Li, Dr.
Contact
pineneedle@sina.com
010-83572418
Zihao Tao, Dr.
Contact
taozihao@pku.edu.cn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Disitamab vedotin

Start the discussion